Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Alvarez

Showing results (471-480 of 644) with videos related to

Pageof 65
Sort By:
Journal of the National Cancer Institute|May 16, 2002
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirusAkseli Hemminki, Kurt R Zinn, Bin Liu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 10, 2006
Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology groupA Calkins, F B Stehman, B Bundy, et al.
Gynecologic Oncology|September 11, 2017
Values and worries of ovarian cancer patientsMaria Pisu, Kelly M Kenzik, Sun Hee Rim, et al.
Gynecologic Oncology|January 8, 2008
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer modelJames E Kendrick, J Michael Straughn, Patsy G Oliver, et al.
Gynecologic Oncology|May 22, 2014
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancerMonjri M Shah, Zachary C Dobbin, Somaira Nowsheen, et al.
Clinical and Experimental Immunology|October 23, 2004
The lung cytokine microenvironment influences molecular events in the lymph nodes during Th1 and Th2 respiratory mucosal sensitization to antigen in vivoS A Ritz, M J Cundall, B U Gajewska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group studyF M Muggia, P S Braly, M F Brady, et al.
Cell & Bioscience|March 6, 2014
Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cellsShiwen Peng, Liwen Song, Jayne Knoff, et al.
Virology|July 3, 2004
Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosisZeng B Zhu, Sharmila K Makhija, Baogen Lu, et al.
Gynecologic Oncology|March 1, 2018
Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment ClinicDavid A Barrington, Macie L Champion, Teresa K L Boitano, et al.
Pageof 65

Showing results (471-480 of 644) with videos related to

Sort By:
Pageof 65
Journal of the National Cancer Institute|May 16, 2002
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirusAkseli Hemminki, Kurt R Zinn, Bin Liu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 10, 2006
Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology groupA Calkins, F B Stehman, B Bundy, et al.
Gynecologic Oncology|September 11, 2017
Values and worries of ovarian cancer patientsMaria Pisu, Kelly M Kenzik, Sun Hee Rim, et al.
Gynecologic Oncology|January 8, 2008
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer modelJames E Kendrick, J Michael Straughn, Patsy G Oliver, et al.
Gynecologic Oncology|May 22, 2014
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancerMonjri M Shah, Zachary C Dobbin, Somaira Nowsheen, et al.
Clinical and Experimental Immunology|October 23, 2004
The lung cytokine microenvironment influences molecular events in the lymph nodes during Th1 and Th2 respiratory mucosal sensitization to antigen in vivoS A Ritz, M J Cundall, B U Gajewska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group studyF M Muggia, P S Braly, M F Brady, et al.
Cell & Bioscience|March 6, 2014
Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cellsShiwen Peng, Liwen Song, Jayne Knoff, et al.
Virology|July 3, 2004
Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosisZeng B Zhu, Sharmila K Makhija, Baogen Lu, et al.
Gynecologic Oncology|March 1, 2018
Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment ClinicDavid A Barrington, Macie L Champion, Teresa K L Boitano, et al.
Pageof 65